About

Ideally, for hair loss prevention you would want to have an anabolic in your body that fulfills all of the anabolic properties of Testosterone and simultaneously has as minimal of an androgenic effect as possible. A small retrospective study reported that finasteride was effective in the treatment of acne in women with normal testosterone levels. In 1997, Merck was successful in obtaining FDA approval for a second indication of finasteride (1 mg) for treatment of male pattern hair loss, which was marketed under the brand name Propecia. In parallel, circulating levels of testosterone increase by approximately 10%, while local concentrations of testosterone in the prostate gland increase by about 7-fold and local testosterone levels in hair follicles increase by around 27–53%. In the United States, finasteride and minoxidil are the only two FDA-approved drugs for the treatment of male pattern hair loss as of 2017. We randomly assigned 43 hypogonadal men to twice daily oral doses of 150, 250 or 400 mg testosterone with 0.25 mg dutasteride, 400 mg testosterone alone or 0.25 mg dutasteride alone for 28 days in a multicenter study. Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in older men with low serum T.
The combination of TU and dutasteride considerably improved serum testosterone levels, alleviated TD symptoms, and effectively reduced PV in patients with TD and BPH. Therefore, we exam-ined the effects of long-acting parenteral testosterone undecanoate (TU) and dutasteride used in combination for the treatment of BPH patients with TD. For all patients the BMI and serum testosterone levels were checked at baseline and after 1 year of treatment. I will delve into this topic further in future articles, but to the extent of how much Dutasteride will increase serum Testosterone and scalp Testosterone levels, the statistics outlined above are what you need to know and take into consideration when designing a hair loss prevention protocol. With that being said, when it comes to a trade off of suppressing 51% of scalp DHT for a 99% increase in scalp Testosterone, the net result will often be less hair loss for most individuals simply due to the high binding affinity and androgenicity of DHT relative to Testosterone.
The only time it wouldn’t apply is if someone was experiencing temporary shedding from a deficiency, hormone imbalance, autoimmune condition, disease, or an array of other possibilities that cause shedding, which should not to be confused with androgenic alopecia. I\'ve had a high sensitivity C-reactive protein test many times now to assess my levels of systemic inflammation, and the tests can\'t even detect inflammation in my body. Low estrogen can cause telogen effluvium (shedding, not androgenic alopecia) as well, which should be noted. I\'ve crashed my estrogen to zero intentionally to dry out for competitions – still had a hair loss. I get everything checked extensively several times per year because if something is causing my hair loss (or results in a real health concern), I want to know what it is.
All subjects discontinued T replacement therapy for 7 days if they used a T gel, patch, buccal or oral T formulation, or for at least 2 weeks if they used intramuscular T. Serum T, DHT and E2 were measured by a validated gas chromatography/tandem mass spectrometry assay at a central laboratory, as described previously.18 Normal ranges were T 300 to 1,000 ng/dl, DHT 30 to 90 ng/dl and E2 10 to 60 pg/ml. Intramuscular injections must be given every 1 to 3 weeks to maintain normal serum T and they can be painful.7 Patches can cause skin reactions in more than half of subjects.8 T gels are safe and effective9 but expensive. Testosterone, the most important male sex hormone, is crucial for male health. Compared with day 1, testosterone was decreased after 28 days of administration.
Oral T administration in this study did not cause liver inflammation and most adverse events were minor. To our knowledge whether additional increases in metabolism would continue with longer treatment is unknown but for some medications this effect stabilizes with time. A drawback to our study was the relatively few men per group, the number who did not complete the study, and the lack of homogeneity in age and baseline T. Thus, future studies will focus on formulations with modified release characteristics for dose optimization to maintain Tavg in the normal range and maximum T below a reasonable level. There were no significant changes in hemoglobin and blood counts, serum chemistry, or markers of liver inflammation or PSA (data not shown). There were 16 nonserious adverse events without evidence of clustering to a specific treatment, of which the most common were headache, dizziness, upper respiratory infection, vomiting, back pain and frequent urination in 2 men each.
Serum E2 was normal throughout the 24-hour period on days 1 and 28 in all treatment groups (fig. 2, E and F). Mean serum T was supraphysiological throughout the 24-hour period on days 1 and 28 in the 400 mg T plus D group and below the lower limit of the normal range in the D alone group. Three men failed to complete the study, 2 were discontinued due to missed visits early in the protocol and 1 withdrew voluntarily. Of the remaining 35 subjects 5 to 8 were assigned to a given treatment group (table 1). Due to large variances and the large number of multiple comparisons hormonal concentrations at each time point on days 1 and 28 are shown in descriptive fashion. The primary end points were to evaluate Tavg during 24 hours in each treatment group on days 1 and 28, and the percent of subjects in each treatment group in whom Tavg was within the normal range. The study was approved by the institutional review boards at each clinical site and each subject provided signed informed consent before participation.